Vaxxas' proprietary Nanopatch™ technology is a needle-free vaccine delivery solution.

Vaxxas’ proprietary Nanopatch™ vaccine delivery platform provides an optimized, differentiated needle-free vaccine delivery solution that safely and cost effectively amplifies vaccine efficacy.  The Nanopatch™ comprises an array of thousands of microprojections that perforate into the outer layers of the skin when applied with an applicator device. The tips of the microprojections are coated with a vaccine material and release this material directly to the large numbers of key immune cells immediately below the skin surface.

Application of the Nanopatch™ to the skin is designed to be pain-free and vaccine delivery and has been shown in preclinical and clinical studies to result in a potent immune response. The robust immune response inherent to Nanopatch-delivered vaccines can enable reduction or elimination of additives such as adjuvants and proprietary dry-coating of vaccine to the Nanopatch™ can eliminate the need for refrigeration during storage and transportation.

Brandon Capital is aware of scammers impersonating us - offering jobs and asking for bank details. We do not offer employment or ask for banking details via SMS, websites or phone calls. Do not provide any details and report to the relevant authorities in your location.